BUZZ-Kezar gains on Aurinia buyout deal

Aurinia Pharmaceuticals Inc. -0.99%
KEZAR LIFE SCIENCES, INC. +0.83%

Aurinia Pharmaceuticals Inc.

AUPH

15.98

-0.99%

KEZAR LIFE SCIENCES, INC.

KZR

7.33

+0.83%

** Shares of biotech firm Kezar Life Sciences KZR.O rise 16.94% to $7.25

** Aurinia Pharmaceuticals AUPH.O says it will buy KZR for $6.955 in cash per share and a contingent value right

** Based on Reuters' calculations, the cash part of the deal is valued at about $51 million

** The contingent value right could give KZR shareholders extra payments later, depending on the progress or sale of Kezar's lead drug, zetomipzomib, as well as certain other assets

** AUPH says zetomipzomib is being developed for autoimmune hepatitis, lupus nephritis and systemic lupus erythematosus

** Says deal is expected to close in Q2 2026

** KZR shares fell more than 6% in 2025


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.